A new trading day began on Tuesday, with Takeda Pharmaceutical Co ADR (NYSE: TAK) stock price up 0.38% from the previous day of trading, before settling in for the closing price of $13.18. TAK’s price has ranged from $13.17 to $17.11 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 14.64%. Meanwhile, its annual earnings per share averaged -59.08%. With a float of $3.14 billion, this company’s outstanding shares have now reached $3.14 billion.
Let’s determine the extent of company efficiency that accounts for 49095 employees.
Takeda Pharmaceutical Co ADR (TAK) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Takeda Pharmaceutical Co ADR is 0.02%, while institutional ownership is 5.44%. The most recent insider transaction that took place on Jan 24 ’24, was worth 29,999,994. In this transaction 10% Owner of this company sold 3,703,703 shares at a rate of $8.10, taking the stock ownership to the 3,755,583 shares.
Takeda Pharmaceutical Co ADR (TAK) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 145.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -59.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.02% during the next five years compared to -6.94% drop over the previous five years of trading.
Takeda Pharmaceutical Co ADR (NYSE: TAK) Trading Performance Indicators
Here are Takeda Pharmaceutical Co ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.40. Likewise, its price to free cash flow for the trailing twelve months is 11.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.40, a number that is poised to hit 0.03 in the next quarter and is forecasted to reach 0.47 in one year’s time.
Technical Analysis of Takeda Pharmaceutical Co ADR (TAK)
Looking closely at Takeda Pharmaceutical Co ADR (NYSE: TAK), its last 5-days average volume was 2.35 million, which is a jump from its year-to-date volume of 1.87 million. As of the previous 9 days, the stock’s Stochastic %D was 5.43%. Additionally, its Average True Range was 0.18.
During the past 100 days, Takeda Pharmaceutical Co ADR’s (TAK) raw stochastic average was set at 3.16%, which indicates a significant decrease from 5.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 13.65% in the past 14 days, which was lower than the 15.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.23, while its 200-day Moving Average is $14.67. However, in the short run, Takeda Pharmaceutical Co ADR’s stock first resistance to watch stands at $13.28. Second resistance stands at $13.33. The third major resistance level sits at $13.36. If the price goes on to break the first support level at $13.20, it is likely to go to the next support level at $13.17. Should the price break the second support level, the third support level stands at $13.12.
Takeda Pharmaceutical Co ADR (NYSE: TAK) Key Stats
With a market capitalization of 41.51 billion, the company has a total of 3,164,818K Shares Outstanding. Currently, annual sales are 29,803 M while annual income is 2,346 M. The company’s previous quarter sales were 7,556 M while its latest quarter income was 718,900 K.
